← back to search

Jean K. Mah

University of Calgary · CA
Area of research
Molecular Biology · Genetics
Research interest
Research interests include Muscle Physiology and Disorders, Neurogenetic and Muscular Disorders Research, Multiple Sclerosis Research Studies, and Cardiomyopathy and Myosin Studies.
h-index
54
citations
10,339
works
239
NIH funding
primary concept
email

Recent publications

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology 2024cited by 113position: middledoi
P76 The Canadian neuromuscular disease registry: a national spinal muscular atrophy registry for real world evidence
Neuromuscular Disorders 2023cited by 0position: middledoi
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy
JAMA Neurology 2022cited by 124position: middledoi
Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy
JAMA 2022cited by 119position: middledoi
Machine learning classification of multiple sclerosis in children using optical coherence tomography
Multiple Sclerosis Journal 2022cited by 25position: middledoi
Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab
Journal of Neurology 2022cited by 23position: middledoi
Bi-allelic variants in neuronal cell adhesion molecule cause a neurodevelopmental disorder characterized by developmental delay, hypotonia, neuropathy/spasticity
The American Journal of Human Genetics 2022cited by 21position: middledoi
Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy
Scientific Reports 2022cited by 10position: middledoi
Corneal nerve and nerve conduction abnormalities in children with type 1 diabetes
Pediatric Diabetes 2022cited by 5position: middledoi
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
The Lancet Neurology 2021cited by 211position: middledoi
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Neurotherapeutics 2021cited by 44position: middledoi
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
JAMA Neurology 2020cited by 258position: middledoi
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
Neuromuscular Disorders 2020cited by 65position: middledoi
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy
Journal of Comparative Effectiveness Research 2020cited by 63position: middledoi
Early corneal nerve fibre damage and increased Langerhans cell density in children with type 1 diabetes mellitus
Scientific Reports 2019cited by 64position: middledoi
Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
Scientific Reports 2019cited by 57position: middledoi
MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement
Acta Neuropathologica 2019cited by 48position: middledoi
Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study
Diabetologia 2018cited by 154position: middledoi
A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial
Trials 2018cited by 53position: middledoi
Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
The Lancet 2017cited by 467position: middledoi
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet 2017cited by 453position: middledoi
A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy
Neurology 2017cited by 73position: middledoi
Developing standardized corticosteroid treatment for Duchenne muscular dystrophy
Contemporary Clinical Trials 2017cited by 67position: middledoi
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
Nature Communications 2017cited by 65position: middledoi
Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial
Quality of Life Research 2017cited by 19position: middledoi
The Role of <i>PIEZO2</i> in Human Mechanosensation
New England Journal of Medicine 2016cited by 467position: middledoi
Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
Muscle & Nerve 2016cited by 229position: middledoi
<i>DMD</i> genotypes and loss of ambulation in the CINRG Duchenne Natural History Study
Neurology 2016cited by 167position: middledoi
Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy
The American Journal of Human Genetics 2016cited by 73position: middledoi
Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes
Journal of the International Neuropsychological Society 2016cited by 15position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Craig M. McDonald · Veterans Affairs Canada5 papers (2015–2022)Eric P. Hoffman · Veterans Affairs Canada3 papers (2015–2020)Paula R. Clemens · University of Pittsburgh3 papers (2015–2020)Cuixia Tian · Shandong University3 papers (2020–2022) · 3 papers (2020–2022)Hoda Abdel‐Hamid · KU Leuven3 papers (2020–2022)Kathryn R. Wagner · Kennedy Krieger Institute3 papers (2020–2022)Craig Campbell · London Health Sciences Centre3 papers (2016–2023)Michela Guglieri · Newcastle upon Tyne Hospitals NHS Foundation Trust3 papers (2020–2022)Sarah P. Sherlock · Indiana University3 papers (2020–2022)Rayaz A. Malik · Manchester Academic Health Science Centre3 papers (2018–2022)Kenneth Romanchuk · Alberta Children's Hospital3 papers (2018–2022)Lawrence Charnas · National Institute of Neurological Disorders and Stroke3 papers (2020–2022)Danièle Pacaud · University of Calgary3 papers (2018–2022)Russell J. Butterfield · University of Utah3 papers (2020–2022)E. Ann Yeh · University of Toronto3 papers (2016–2022) · 3 papers (2020–2022)Brenda Banwell · Johns Hopkins University3 papers (2016–2022)Francesco Muntoni · Great Ormond Street Hospital2 papers (2022–2022)Anne M. Connolly · Nationwide Children's Hospital2 papers (2020–2021)